- Tytuł:
-
Aktywność biologiczna modyfikowanych nukleozydów. Część 3
Biological activity of modified nucleosides. Part 3 - Autorzy:
- Szlenkier, M.
- Powiązania:
- https://bibliotekanauki.pl/articles/171517.pdf
- Data publikacji:
- 2018
- Wydawca:
- Polskie Towarzystwo Chemiczne
- Tematy:
-
nukleozydy modyfikowane
aktywność biologiczna
cele molekularne
mechanizm działania
modified nucleosides
biological activity
molecular targets
mechanism of action - Opis:
- Part III of the review devoted to biological activities of nucleoside derivatives presents a further description of analogues modified in the sugar residue with particular focus on those with altered configuration in the 2’ or 3’ position, e.g. cytarabine – an old anticancer chemotherapy agent used to treat acute myeloid leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphomas; fludarabine – derivative of vidarabine used as a drug in the treatment of chronic lymphocytic leukemia, and non-Hodgkin lymphomas; clofarabine – approved by the FDA in 2004, a new-generation second-line drug for recurrent acute myeloid leukemia; and fialuridine – examined as a potential therapeutic for the treatment of HBV infection, however, clinical trials ended tragically. In the last section of the review derivatives with other modifications in the sugar moiety are described – carbocyclic and acyclic analogues, l-nucleosides and 5’-modified nucleosides. Among others, very important modified nucleosides are listed e.g. acyclovir, ganciclovir, DHPA, tenofovir, cyclopentenylcytosine, entecavir, carbovir, abacavir, lamivudine, telbivudine and sinefungin VA. All parts together make a possibly complete and concise review, including the latest reports, the most important groups of modified nucleosides, and should be considered as a whole. In the context of the activities description, there are references to the important molecular targets, mechanisms of action, pharmacodynamics, pharmacokinetics, toxicity, resistance, in vitro and in vivo tests or prodrug strategies, which can be a starting point for further study for chemists interested in medicinal chemistry.
- Źródło:
-
Wiadomości Chemiczne; 2018, 72, 9-10; 767-787
0043-5104
2300-0295 - Pojawia się w:
- Wiadomości Chemiczne
- Dostawca treści:
- Biblioteka Nauki
Artykuł